Biology:Tissue plasminogen activator

From HandWiki
Revision as of 07:47, 16 March 2024 by JMinHep (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Protein involved in the breakdown of blood clots


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Tissue plasminogen activator (abbreviated tPA or PLAT) is a protein involved in the breakdown of blood clots. It is a serine protease (EC 3.4.21.68) found on endothelial cells, the cells that line the blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Human tPA has a molecular weight of ~70 kDa in the single-chain form.[1]

tPA can be manufactured using recombinant biotechnology techniques; tPA produced by such means are referred to as recombinant tissue plasminogen activator (rtPA). Specific rtPAs include alteplase, reteplase, and tenecteplase. They are used in clinical medicine to treat embolic or thrombotic stroke. The use of this protein is contraindicated in hemorrhagic stroke and head trauma. The antidote for tPA in case of toxicity is aminocaproic acid.

Medical uses

tPA is used in some cases of diseases that feature blood clots, such as pulmonary embolism, myocardial infarction, and stroke, in a medical treatment called thrombolysis. The most common use is for ischemic stroke. It can either be administered systemically, in the case of acute myocardial infarction, acute ischemic stroke, and most cases of acute massive pulmonary embolism, or administered through an arterial catheter directly to the site of occlusion in the case of peripheral arterial thrombi and thrombi in the proximal deep veins of the leg.[2]

Ischemic stroke

Statistics

There have been 12 large scale, high-quality trials of rtPA in acute ischemic stroke. A meta-analysis of these trials concluded that rtPA given within 6 hours of a stroke significantly increased the odds of being alive and independent at final follow-up, particularly in patients treated within 3 hours. However a significant mortality rate was noted, mostly from intracranial haemorrhage at 7 days, but later mortality was not significant amongst treated and non-treated patients.[3]

It has been suggested that if tPA is effective in ischemic stroke, it must be administered as early as possible after the onset of stroke symptoms, given that patients present to an ED in a timely manner.[3][4] Many national guidelines including the AHA have interpreted this cohort of studies as suggesting that there are specific subgroups who may benefit from tPA and thus recommend its use within a limited time window after the event. Protocol guidelines require its use intravenously within the first three hours of the event, after which its detriments may outweigh its benefits.

For example, the Canadian Stroke Network guideline states "All patients with disabling acute ischemic stroke who can be treated within 4.5 hours of symptom onset should be evaluated without delay to determine their eligibility for treatment" with tPA.[5] Delayed presentation to the ED leads to decreased eligibility; as few as 3% of people qualify for this treatment.[6] Similarly in the United States, the window of administration used to be 3 hours from onset of symptoms, but the newer guidelines also recommend use up to 4.5 hours after symptom onset, depending on the patient's presentation, past medical history, current comorbidities and medication usage.[7] tPA appears to show benefit not only for large artery occlusions but also for lacunar strokes. Since tPA dissolves blood clots, there is risk of hemorrhage with its use.[8][9]

Administration criteria

Use of tPA in the United States in treatment of patients who are eligible for its use, have no contraindications, and arrival at the treating facility less than 3 hours after onset of symptoms, is reported to have doubled from 2003 to 2011. Use on patients with mild deficits, of nonwhite race/ethnicity, and oldest old age increased. However, many patients who were eligible for treatment were not treated.[10][11]

tPA has also been given to patients with acute ischemic stroke above age 90 years old. Although a small fraction of patients 90 years and above treated with tPA for acute ischemic stroke recover, most patients have a poor 30-day functional outcome or die.[12] Nonagenarians may do as well as octogenarians following treatment with IV-tPA for acute ischemic stroke.[13] In addition, people with frostbite treated with tPA had fewer amputations than those not treated with tPA.[14]

General consensus on use

There is consensus amongst stroke specialists that tPA is the standard of care for eligible stroke patients, and benefits outweigh the risks. There is significant debate mainly in the emergency medicine community regarding recombinant tPA's effectiveness in ischemic stroke. The NNT Group on evidence-based medicine concluded that it was inappropriate to combine these twelve trials into a single analysis, because of substantial clinical heterogeneity (i.e., variations in study design, setting, and population characteristics).[15] Examining each study individually, the NNT group noted that two of these studies showed benefit to patients given tPA (and that, using analytical methods that they think flawed); four studies showed harm and had to be stopped before completion; and the remaining studies showed neither benefit nor harm. On the basis of this evidence, the NNT Group recommended against the use of tPA in acute ischaemic stroke.[15] The NNT Group notes that the case for the 3-hour time window arises largely from analysis of two trials: NINDS-2 and subgroup results from IST-3. "However, presuming that early (0-3h) administration is better than later administration (3-4.5h or 4.5-6h) the subgroup results of IST-3 suggest an implausible biological effect in which early administration is beneficial, 3-4.5h administration is harmful, and 4.5-6h administration is again beneficial."[15] Indeed, even the original publication of the IST-3 trial found that time-window effects were not significant predictors of outcome (p=0.61).[16] In the UK, concerns by stroke specialists have led to a review by the Medicines and Healthcare products Regulatory Agency.[17]

Pulmonary embolism

Pulmonary embolism (blood clots that have moved to the lung arteries) is usually treated with heparin generally followed by warfarin. If pulmonary embolism causes severe instability due to high pressure on the heart ("massive PE") and leads to low blood pressure, recombinant tPA is recommended.[18][19][20]

Recombinant tissue plasminogen activators (r-tPA)

tPA was first produced by recombinant DNA techniques at Genentech in 1982.[21]

Tissue-type plasminogen activators were initially identified and isolated from mammalian tissues after which a cDNA library was established with the use of reverse transcriptase and mRNA from human melanoma cells. The aforementioned mRNA was isolated using antibody based immunoprecipitation. The resulting cDNA library was subsequently screened via sequence analysis and compared to a whole genome library for confirmation of specific protein isolation and accuracy. cDNA was cloned into a synthetic plasmid and initially expressed in E. coli cells, followed by yeast cells with successful results confirmed via sequencing before attempting in mammalian cells. The transformants were selected with the use of Methotrexate. Methotrexate strengthens selection by inhibiting DHFR activity which then compels the cells to express more DHFR (exogenous) and consequently more recombinant protein to survive. The highly active transformants were subsequently placed in an industrial fermenter. The tPA which was then secreted into the culture medium was isolated and collected for therapeutic use. For pharmaceutical purposes, tPA was the first pharmaceutical drug produced synthetically with the use of mammalian cells, specifically Chinese hamster ovarian cells (CHO). Recombinant tPA is commonly referred to as r-tPA and sold under multiple brand names.[22][23]

Commercial r-tPA
Product Name Notes
Activase (Alteplase) FDA-approved for treatment of myocardial infarction with ST-elevation (STEMI), acute ischemic stroke (AIS), acute massive pulmonary embolism, and central venous access devices (CVAD).[24]
Reteplase FDA-approved for acute myocardial infarction, where it has more convenient administration and faster thrombolysis than alteplase. This is because it is a second generation engineered TPA, hence its half life is up to 20 minutes which allows it to be administered as a bolus injection rather than an infusion like Alteplase.[24]
Tenecteplase Indicated in acute myocardial infarction, showing fewer bleeding complications but otherwise similar mortality rates after one year compared to Alteplase.[24]

Interactions

Tissue plasminogen activator has been shown to interact with:


Function

A simplified illustration demonstrates clot breakdown (fibrinolysis), with blue arrows denoting stimulation, and red arrows inhibition.

tPA and plasmin are the key enzymes of the fibrinolytic pathway in which tPA-mediated plasmin generation occurs.

To be specific, tPA cleaves the zymogen plasminogen at its Arg561 - Val562 peptide bond, into the serine protease plasmin.[citation needed]

Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding and/or an increase of the vascular permeability.[30] Decreased activity leads to hypofibrinolysis, which can result in thrombosis or embolism.

In ischemic stroke patients, decreased tPA activity was reported to be associated with an increase in plasma P-selectin concentration.[31]

Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.[citation needed]

Physiology and regulation

In vivo mechanism of action of tPA within the fibrinolytic system. tPA can go one of three ways in the body; (1) uptaken by the liver and cleared through receptors therein, (2) inhibited by a plasminogen activator inhibitor (PAI) and subsequently cleared from the liver, or (3) through the activation of plasminogen to plasmin for degradation to result in fibrin degradation product (FDP).[32][33]

Once in the body, tPA has three main routes it can take, with one resulting in desired thrombolytic activity (see figure). For starters, following administration and release, tPA can be absorbed by the liver and cleared from the body through receptors present therein. One of the specific receptors responsible for this processes is a scavenger protein, specifically the LDL Receptor-Related Protein (LRP1).[33] tPA additionally can be bound by a plasminogen activator inhibitor (PAI), resulting in inactivation of its activity, and following clearing from the body by the liver. Lastly, tPA can bind plasminogen, cleaving off the bound plasmin from it. Plasmin, another type of protease, can either be bound by a plasmin inhibitor, or work to degrade fibrin clots, which is the highest utilized and desired pathway.[32]

Synaptic plasticity

tPA is known to participate in some forms of synaptic plasticity, in particular long-term depression and consequently mediate some aspects of memory.[34]

Genetics

Tissue plasminogen activator is a protein encoded by the PLAT gene, which is located on chromosome 8. The primary transcript produced by this gene undergoes alternative splicing, producing three distinct messenger RNAs.[35]

Gallery

A theoretical full-length model of t-PA. The finger domain is in red, the EGF-like domain in green, the kringle 1 and 2 domains in blue and yellow respectively, and the serine protease domain in magenta.
A 360 view of t-PA showing its structure.

See also

References

  1. ↑ "Tissue plasminogen activator human". Sigma-Aldrich. 9 July 2017. https://www.sigmaaldrich.com/catalog/product/sigma/t5451?lang=en&region=US. 
  2. ↑ Thrombolytic Therapy. 2008-11-20. http://emedicine.medscape.com/article/811234-overview+eMedicine+Specialties. 
  3. ↑ 3.0 3.1 "Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis". Lancet 379 (9834): 2364–72. June 2012. doi:10.1016/S0140-6736(12)60738-7. PMID 22632907. 
  4. ↑ "Tissue plasminogen activator and stroke: review of the literature for the clinician". The Journal of Emergency Medicine 43 (6): 1149–54. December 2012. doi:10.1016/j.jemermed.2012.05.005. PMID 22818644. 
  5. ↑ "Hyperacute stroke management". Canadian best practice recommendations for stroke care. Ottawa, ON: Canadian Stroke Network. Dec 8, 2010. pp. 55–84. http://www.guideline.gov/content.aspx?id=34088. Retrieved 30 November 2013. 
  6. ↑ "Patient delay in acute stroke response". European Journal of Neurology 15 (4): 315–6. April 2008. doi:10.1111/j.1468-1331.2008.02083.x. PMID 18353121. 
  7. ↑ "4.5 hours: the new time window for tissue plasminogen activator in stroke". Stroke 40 (6): 2266–7. June 2009. doi:10.1161/STROKEAHA.108.544171. PMID 19407232. 
  8. ↑ "Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke". Cell Mol Neurobiol 42 (3): 621–46. April 2022. doi:10.1007/s10571-020-00985-1. PMID 33125600. 
  9. ↑ "Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia". Neurobiol Dis 108: 173–182. December 2017. doi:10.1016/j.nbd.2017.08.011. PMID 28830843. 
  10. ↑ "Clot-Busting Drugs Used More Often in Stroke". Medpage Today. 2013-08-23. http://www.medpagetoday.com/Cardiology/Strokes/41156. 
  11. ↑ "Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals". Circulation: Cardiovascular Quality and Outcomes 6 (5): 543–9. September 2013. doi:10.1161/CIRCOUTCOMES.111.000095. PMID 24046398. "The frequency of IV tPA use among all AIS patients, regardless of contraindications, nearly doubled from 2003 to 2011. Treatment with tPA has expanded to include more patients with mild deficits, nonwhite race/ethnicity, and oldest old age". 
  12. ↑ "Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older". Mayo Clinic Proceedings 84 (4): 334–8. April 2009. doi:10.1016/S0025-6196(11)60542-9. PMID 19339651. 
  13. ↑ "Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians". Stroke 41 (8): 1833–5. August 2010. doi:10.1161/STROKEAHA.110.586438. PMID 20576948. 
  14. ↑ "An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite". J Trauma 59 (6): 1350–1354. 2005. doi:10.1097/01.ta.0000195517.50778.2e. PMID 16394908. ; and repeated by "Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy". Archives of Surgery 142 (6): 546–51; discussion 551–3. June 2007. doi:10.1001/archsurg.142.6.546. PMID 17576891. 
  15. ↑ 15.0 15.1 15.2 Newman, David (March 25, 2013). "Thrombolytics for Acute Ischemic Stroke: No benefit found". NNT Group. http://www.thennt.com/nnt/thrombolytics-for-stroke/. 
  16. ↑ "The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3): a randomised controlled trial"]. Lancet 379 (9834): 2352–63. June 2012. doi:10.1016/S0140-6736(12)60768-5. PMID 22632908. 
  17. ↑ Brimelow, Adam (2014-08-22). "Safety review into stroke clot-buster drug alteplase". British Broadcasting Corporation. https://www.bbc.co.uk/news/health-28900824. 
  18. ↑ "2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism". European Heart Journal 35 (43): 3033–69, 3069a–3069k. November 2014. doi:10.1093/eurheartj/ehu283. PMID 25173341. 
  19. ↑ National Institute for Health and Clinical Excellence. Clinical guideline 144: Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. London, 2012.
  20. ↑ "Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest 133 (6 Suppl): 71S–109S. June 2008. doi:10.1378/chest.08-0693. PMID 18574259. 
  21. ↑ "(TPA) Produced By Recombinant DNA Techniques". Biology Discussion. 1982-07-23. https://www.gene.com/media/press-releases/4185/1982-07-23/tpa-produced-by-recombinant-dna-techniqu. 
  22. ↑ "Pharmaceutical Products of Recombinant DNA Technology". Biology Discussion. 2015-09-21. http://www.biologydiscussion.com/dna/pharmaceutical-products-of-recombinant-dna-technology/10015.. 
  23. ↑ "Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli". Nature 301 (5897): 214–21. January 1983. doi:10.1038/301214a0. PMID 6337343. Bibcode: 1983Natur.301..214P. 
  24. ↑ 24.0 24.1 24.2 Wanda L Rivera-Bou; José G Cabañas; Salvador E Villanueva (2017-05-02). "Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction". Medscape. http://emedicine.medscape.com/article/811234-overview+eMedicine+Specialties. 
  25. ↑ "Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains". Biochemistry 40 (3): 801–8. January 2001. doi:10.1021/bi001789t. PMID 11170397. 
  26. ↑ "Localization of the binding site of tissue-type plasminogen activator to fibrin". The Journal of Clinical Investigation 78 (1): 163–9. July 1986. doi:10.1172/JCI112546. PMID 3088041. 
  27. ↑ "Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation". The Journal of Neuroscience 20 (2): 542–9. January 2000. doi:10.1523/JNEUROSCI.20-02-00542.2000. PMID 10632583. 
  28. ↑ "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor". Proceedings of the National Academy of Sciences of the United States of America 89 (16): 7422–6. August 1992. doi:10.1073/pnas.89.16.7422. PMID 1502153. Bibcode: 1992PNAS...89.7422O. 
  29. ↑ "Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells". Journal of Neurochemistry 82 (6): 1406–15. September 2002. doi:10.1046/j.1471-4159.2002.01100.x. PMID 12354288. 
  30. ↑ "Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism". Blood 128 (20): 2423–2434. November 2016. doi:10.1182/blood-2016-03-705384. PMID 27531677. 
  31. ↑ "Association between platelet activation and fibrinolysis in acute stroke patients". Neuroscience Letters 384 (3): 305–9. August 2005. doi:10.1016/j.neulet.2005.04.090. PMID 15916851. 
  32. ↑ 32.0 32.1 "Tissue Plasminogen Activator (tPA)". http://diapharma.com/tissue-plasminogen-activator-tpa/. 
  33. ↑ 33.0 33.1 "Tissue-type plasminogen activator as a therapeutic target in stroke". Expert Opinion on Therapeutic Targets 12 (2): 159–70. February 2008. doi:10.1517/14728222.12.2.159. PMID 18208365. 
  34. ↑ "Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory". The European Journal of Neuroscience 12 (3): 1002–1012. March 2000. doi:10.1046/j.1460-9568.2000.00991.x. PMID 10762331. https://pubmed.ncbi.nlm.nih.gov/10762331/. 
  35. ↑ PLAT_ plasminogen activator, tissue type [ Homo sapiens (human) ], NCBI gene database Gene ID: 5327 https://www.ncbi.nlm.nih.gov/gene/5327

External links




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Tissue_plasminogen_activator&oldid=3722023"